C12N 2840/44
Being a specific part of the splice mechanism
Official title: being a specific part of the splice mechanism, e.g. donor, acceptor
C12N2840/44 (Being a specific part of the splice mechanism) appears on 395 US grants and 453 published applications in this corpus.
Search patents in C12N- Granted patents
- 395
- Published applications
- 453
- Assignees
- 259
- Inventors
- 848
- Latest grant
- 2 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 2 | 0 |
| 1990 | 2 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 2 | 0 |
| 1994 | 0 | 0 |
| 1995 | 2 | 0 |
| 1996 | 9 | 0 |
| 1997 | 20 | 0 |
| 1998 | 30 | 0 |
| 1999 | 20 | 0 |
| 2000 | 32 | 0 |
| 2001 | 21 | 5 |
| 2002 | 23 | 39 |
| 2003 | 21 | 50 |
| 2004 | 15 | 34 |
| 2005 | 12 | 39 |
| 2006 | 13 | 30 |
| 2007 | 16 | 14 |
| 2008 | 16 | 10 |
| 2009 | 12 | 18 |
| 2010 | 12 | 13 |
| 2011 | 7 | 10 |
| 2012 | 5 | 18 |
| 2013 | 5 | 8 |
| 2014 | 10 | 9 |
| 2015 | 6 | 8 |
| 2016 | 9 | 6 |
| 2017 | 4 | 7 |
| 2018 | 4 | 11 |
| 2019 | 6 | 6 |
| 2020 | 2 | 12 |
| 2021 | 7 | 13 |
| 2022 | 11 | 20 |
| 2023 | 7 | 14 |
| 2024 | 8 | 27 |
| 2025 | 17 | 15 |
| 2026 | 6 | 17 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Systems and uses thereof for creating synthetic transcriptional logic ‘and’ gates based on pre-mRNA trans-splicing2 Jun 2026US 12,644,130 B2Migal Galilee Research Institute Ltd.
- Compositions and methods for circular RNA expression14 Apr 2026US 12,600,987 B2Duke University
- Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems31 Mar 2026US 12,589,168 B2Regeneron Pharmaceuticals, Inc.
- Compositions and methods for mammalian genetics and uses thereof17 Mar 2026US 12,577,587 B2Whitehead Institute for Biomedical Research
- Circular RNA for translation in eukaryotic cells10 Mar 2026US 12,570,996 B2Massachusetts Institute of Technology
- Expression cassette coding for vascular endothelial growth factor8 Oct 2026US 2026/0308618 A1Cornell University
- Dual aav vectors for treating stargardt disease1 Oct 2026US 2026/0295092 A1Atsena Therapeutics, Inc.
- Methods for generating artificial thymus, products and uses thereof17 Sep 2026US 2026/0275290 A1
- Compositions comprising polyribonucleotides and uses thereof10 Sep 2026US 2026/0263639 A1Flagship Pioneering Innovations VI, LLC
- Circular rna and preparation method thereof10 Sep 2026US 2026/0265772 A1RiboX Therapeutics HK Limited
Most cited
By later US patents
- Transgenic non-human animals capable of producing heterologous antibodies of various isotypes1,748US 5,569,825 AGenPharm International, Inc. · 1996
- Isolation of exogenous recombinant proteins from the milk of transgenic mammals500US 4,873,316 ABiogen, Inc. · 1989
- Preparation of functional human factor VIII in mammalian cells using methotrexate based selection276US 4,965,199 AGenentech, Inc. · 1990
- Transgenic bovine266US 5,741,957 APharming B.V. · 1998
- Eukaryotic layered vector initiation systems204US 5,814,482 A1998